The litigation, spearheaded by the firm Hagens Berman Sobol Shapiro LLP, targets Regeneron’s conduct between August 1, 2025, and May 15, 2026. Plaintiffs allege that management repeatedly misled shareholders regarding the efficacy of Fianlimab in combination with Libtayo, characterizing the therapy as a potential blockbuster even as internal data suggested the trial’s statistical assumptions were flawed.
In section Releases
Regeneron Faces Class Action Lawsuit Following Failed Melanoma Trial
A federal securities class action lawsuit has been filed against Regeneron Pharmaceuticals after the company reported that a pivotal Phase 3 clinical trial for its melanoma therapy failed to meet primary endpoints, triggering an $11 billion market capitalization collapse and drawing scrutiny from federal litigators.
Regeneron management previously attributed the slowing rate of disease progression events to the superior performance of the treatment arm. However, the company eventually admitted to altering its trial protocol in response to these sluggish event rates—a move disclosed to regulators months before investors were notified. By the time the company confirmed the trial’s failure on May 15, 2026, the stock price had already begun a sharp decline. Hagens Berman partner Reed Kathrein stated that the investigation focuses on whether the company intentionally delayed disclosing protocol changes to maintain share value despite knowing the treatment lacked the promised commercial potential. Investors who suffered losses have until September 14, 2026, to file for lead plaintiff status.
Comments (0)
No comments yet. Be the first!